Probe Ranbaxy trades ahead of Sun Pharma deal: brokers

The president of an Indian brokerage association is planning to formally request that India's market regulator investigate trading in Ranbaxy Laboratories shares in the days leading up to its acquisition by Sun Pharmaceutical Industries.

Ranbaxy shares surged 24 per cent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy Ranbaxy for $3.2 billion.

"Because there was such kind of price movement before the deal was announced, we have decided to check with the regulator," Naresh Tejwani, president of the Association of National Exchanges Members of India (ANMI) said on Wednesday.

"We will write to them by the end of the day to investigate into the matter."

A Ranbaxy spokesman declined to comment.

A spokesman for market regulator Securities and Exchange Board of India also declined to comment.

Sun Pharmaceutical did not immediately respond to requests for comment.


Copyright Thomson Reuters 2014